• Title/Summary/Keyword: PCWG3

Search Result 1, Processing Time 0.014 seconds

Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations (전이성 거세 저항성 전립선암의 치료 반응 평가를 위한 뼈스캔 기반의 전이성 골병변 반응 평가 지침: Prostate Cancer Clinical Trial Working Group 3 권장사항)

  • Ji Sung Jang;Amy Junghyun Lee;Kye Jin Park;Kyung Won Kim;Hyo Jung Park
    • Journal of the Korean Society of Radiology
    • /
    • v.84 no.6
    • /
    • pp.1244-1256
    • /
    • 2023
  • In prostate cancer, the bone is the most common site of metastasis, and it is essential to evaluate metastatic bone lesions to assess the tumor burden and treatment response. Castration-resistant prostate cancer refers to the state wherein the cancer continues to progress despite a significant reduction of the sex hormone level and is associated with frequent distant metastasis. The Prostate Cancer Working Group 3 (PCWG3) released guidelines that aimed to standardize the assessment of treatment effects in castration-resistant prostate cancer using bone scintigraphy. However, these guidelines can be challenging to comprehend and implement in practical settings. The purpose of this review was to provide an overview of a specific image acquisition method and treatment response assessment for bone scintigraphy-based evaluation of bone lesions in metastatic castration-resistant prostate cancer, in accordance with the PCWG3 guidelines.